Studies associated with ontology term
MP:0001790   'abnormal immune system physiology'
   
Navigate ontologies  


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Auwerx1 cell signaling molecule detection
with high-fat diet
INF-gamma, interleukins, monocyte chemoattractant, macrophage inflammatory protein, T cell RANTES, TNF-alpha. BXD w/par   (57) m 8-29 wks 2016
Benavides1 genotype assessment Gpr84 allele assessment. PCR, sequencing. inbred w/CC8   (58) both 6wks 2013
Boon1 body weight
with influenza A (H5N1) virus
Influenza A (H5N1) virus (several doses) vs. baseline. inbred   (23) f 6-9wks 2011
Boon1 health assessment
with influenza A (H5N1) virus
Survival rate, influenza A (H5N1) virus (several doses). Strain H5N1 susceptibility score. inbred   (23) f 6-9wks 2011
Bopp1 health assessment
with Plasmodium berghei
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. inbred   (31) both 8-12wks 2010
Brinkmeyer1 body weight
with Theiler's murine encephalomyelitis virus
Body weight CC   (5) both 4wks 2017
Brinkmeyer1 health assessment
with Theiler's murine encephalomyelitis virus
Clinical health assessment scores, TMEV infection. CC   (5) both 4wks 2017
Brinkmeyer1 RNA expression profiling
with Theiler's murine encephalomyelitis virus
TMEV transcript abundance. CC   (5) both 4wks 2017
Brinkmeyer1 open field test
with Theiler's murine encephalomyelitis virus
Locomotor activity, TMEV infection. CC   (5) both 4wks 2017
Brinkmeyer1 gait analysis
with Theiler's murine encephalomyelitis virus
DigiGait analysis and footprint analysis, TMEV infection. CC   (5) both 4wks 2017
Brinkmeyer1 rotarod
with Theiler's murine encephalomyelitis virus
Latency to fall from accelerating rotarod, TMEV infection. CC   (5) both 4wks 2017
Cowell1 health assessment
with Staphylococcus aureus
Survival rate, Staphylococcus aureus. inbred   (13) f 8wks 2012
Cowell1 hormone quantification
with Staphylococcus aureus
Interleukin 6 levels (serum) after infection with Staphylococcus aureus. Kidney and peritoneal fluid. inbred   (13) f 8wks 2012
Cowell1 in vitro assay
with Staphylococcus aureus
Bacterial load after infection with Staphylococcus aureus. Kidney and peritoneal fluid. In vitro assay. inbred   (13) f 8wks 2012
Dietrich1 in vitro assay
with Bacillus anthracis lethal toxin
Bacillus anthracis lethal toxin (anthrax) susceptibility. inbred   (50) f 6-8wks* 1998
Donahue7 immunoglobulin quantification Immunoglobulin concentrations (plasma). B6.A consomic w/par   (22) both 9wks 2012
Donahue8 immunoglobulin quantification Immunoglobulin concentrations (plasma). B6.PWD consomic w/par   (28) both 9wks 2011
Eumorphia7 immunoglobulin quantification Immunoglobulin concentrations (serum). inbred   (6) both 9-12wks 2008
Farmer1 study archive Colitis susceptibility, severity. Colon histopathology, body and spleen weight. QTL population both 6wks 2001
Ferris1 body weight
with influenza A (H1N1) virus
Body weight CC pre w/par   (163) f 8-16wks 2012
Ferris1 health assessment
with influenza A (H1N1) virus
Clinical health assessment score and strain susceptibility index 4 days after infection with influenza A (H1N1) virus. CC pre w/par   (163) f 8-16wks 2012
Ferris1 in vitro assay
with influenza A (H1N1) virus
Viral replication log titer 4 days after infection with influenza A (H1N1) virus. In vitro. CC pre w/par   (163) f 8-16wks 2012
Ferris1 histopathology
with influenza A (H1N1) virus
Lungs and airway 4 days after infection with influenza A (H1N1) virus. CC pre w/par   (163) f 8-16wks 2012
GMC20 immunoglobulin quantification Immunoglobulins (plasma). inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC20 autoantibody quantification Anti-DNA autoantibodies, rheumatoid factor. inbred w/CC8   (8) both 16-17, 20-21wks 2020
Graham1 body weight
with West Nile virus
Body weight CC RIX   (5) m 8-10wks 2015
Graham1 health assessment
with West Nile virus
Clinical score. CC RIX   (5) m 8-10wks 2015
Graham1 immune cell quantification
with West Nile virus
T cell populations in brain and spleen. CC RIX   (5) m 8-10wks 2015
Graham1 RNA expression profiling
with West Nile virus
Viral load and expression of Ifnb1 and Ifit1 in brain, kidney and spleen. CC RIX   (5) m 8-10wks 2015
Graham2 colony observation
with SARS-CoV
Body weight loss and mortality. CC RIX   (117) f 8-10wks 2021
Graham2 in vitro assay
with SARS-CoV
Lung viral load (log10). CC RIX   (117) f 8-10wks 2021
Graham3 immune cell quantification Baseline splenic T cell subsets. CC RIX   (104) m 8-10wks 2021
Gros1 in vitro assay
with Candida albicans
Susceptibility to infection with Candida albicans. inbred   (36) f 8-12wks 2011
Gros1 genotype assessment
with Candida albicans
C5 allele sufficiency or deficiency. inbred   (36) f 8-12wks 2011
Gros2 health assessment
with Plasmodium chabaudi
Survival score and susceptibility, Plasmodium chabaudi. inbred   (25) both 8-10wks 2012
Gros2 microscopy
with Plasmodium chabaudi
Percent of Plasmodium chabaudi-infected erythrocytes in blood. inbred   (25) both 8-10wks 2012
Haston1 bronchoalveolar lavage assessment
with radiation
Bronchoalveolar cell differential after exposure to radiation (18 Gy). inbred   (26) both 15-36wks 2012
Haston1 histopathology
with radiation
Post exposure to radiation. inbred   (26) both 15-36wks 2012
Jax2 MHC haplotype tissue typing Major histocompatibility complex (MHC) H2 haplotype. inbred   (56) both 2000
Mahler1 study archive Colitis susceptibility. Colon histopathology, spleen weight. QTL population both 6wks 2002
Mills1 apoptosis assessment Aging study, 6mo, 12mo, 20mo. inbred   (30) both 26, 52, 87 wks 2008
Mrug1 study archive Kidney morphology. QTL population both 1-2wks 2005
Noll1 immunoglobulin quantification IgM, IgG1, IgG2a + IgG2c, IgG2b, IgG3, total IgG CC RIX   (46) f 8-12 wks of age 2020
Peters1 coagulation test Fibrinogen. inbred w/CC7   (43) both 10wks 2001
Powell1 in vitro assay
with Neisseria musculi
Bacterial load after inoculation with Neisseria musculi. Oral cavity. inbred w/CC8   (8) both 8-16wks 2018
Rodriguez1 study archive Spleen, liver murine cytomegalovirus study. QTL population both 8-12wks 2009
Schughart1 body weight
with influenza A (H1N1) virus
Influenza A (H1N1) virus vs. baseline. Several timepoints. inbred   (9) both 10-12wks 2009
Schughart1 health assessment
with influenza A (H1N1) virus
Strain susceptibility score, influenza A (H1N1) virus. inbred   (9) both 10-12wks 2009
Schughart2 body weight
with influenza A (H1N1) virus
Influenza A (H1N1) virus vs. baseline. Several timepoints.. BXD w/par   (56) f 9-18wks 2012
Schughart2 health assessment
with influenza A (H1N1) virus
Survival rate, susceptibility, influenza A (H1N1) virus. BXD w/par   (56) f 9-18wks 2012
Schughart3 body weight
with influenza A (H3N2) virus
Influenza A (H3N2) virus (several doses) vs. baseline. Several timepoints. inbred w/CC8   (8) both 7-13wks 2013
Schughart3 health assessment
with influenza A (H3N2) virus
Survival rate, susceptibility, influenza A (H3N2) virus (several doses). inbred w/CC8   (8) both 7-13wks 2013
Schughart4 body weight
with influenza A (H3N2) virus
Influenza A (H3N2) virus vs. controls. Several timepoints. inbred w/CC8   (8) f 8-12wks 2016
Schughart4 in vitro assay
with influenza A (H3N2) virus
Viral load in lungs after infection with influenza A (H3N2) virus. inbred w/CC8   (8) f 8-12wks 2016
Schughart5 body weight
with influenza A (H3N2) virus
Influenza A (H3N2) virus vs. controls. Several timepoints. inbred w/CC8   (8) f 8-12wks 2016
Schwartz2 bronchoalveolar lavage assessment
with ovalbumin
Lung inflammatory changes. Ovalbumin vs. control. inbred   (8) m 6-8wks 2001
Sundberg2 study archive Alopecia areata autoimmune disease susceptibility. QTL population both 52wks 2003
Svenson3 coagulation test Fibrinogen, anti-thrombin III, factor VIII B6.PWD consomic w/par   (28) both 9wks 2006
Zaytseva1 glycosylation profile IgG glycan peaks, relative abundance CC   (111) both 4-140wks 2018
Zaytseva2 glycosylation profile IgG subclasses, relative abundance CC   (95) both 20-117wks 2018